Royal Bank Of Canada Uro Gen Pharma Ltd. Transaction History

Royal Bank Of Canada

$471 Billion
Q3 2024

A detailed history of Royal Bank Of Canada transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Royal Bank Of Canada holds 6,124 shares of URGN stock, worth $76,427. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,124

Previous 5,261 16.4%

Holding current value

$76,427

Previous $88,000 12.5%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$12.7 - $17.92 $10,960 - $15,464	863 Added 16.4%	6,124 $77,000
Q2 2024 Aug 14, 2024	SELL	$12.72 - $19.2 $80,950 - $122,188	-6,364 Reduced 54.74%	5,261 $88,000
Q1 2024 Nov 05, 2024	BUY	$13.81 - $19.33 $87,886 - $123,016	6,364 Added 120.97%	11,625 $174,000
Q1 2024 May 15, 2024	SELL	$13.81 - $19.33 $124,262 - $173,931	-8,998 Reduced 43.63%	11,625 $174,000
Q4 2023 Feb 14, 2024	BUY	$10.87 - $15.93 $39,208 - $57,459	3,607 Added 21.2%	20,623 $309,000
Q3 2023 Nov 14, 2023	BUY	$8.84 - $22.64 $6,753 - $17,296	764 Added 4.7%	17,016 $238,000
Q2 2023 Aug 14, 2023	BUY	$8.75 - $14.29 $3,727 - $6,087	426 Added 2.69%	16,252 $168,000
Q1 2023 May 15, 2023	BUY	$7.99 - $11.02 $7,502 - $10,347	939 Added 6.31%	15,826 $146,000
Q4 2022 Feb 14, 2023	BUY	$7.55 - $11.96 $37 - $59	5 Added 0.03%	14,887 $132,000
Q2 2022 Aug 15, 2022	SELL	$5.12 - $8.74 $6,133 - $10,470	-1,198 Reduced 7.45%	14,882 $122,000
Q1 2022 May 16, 2022	SELL	$5.92 - $9.73 $9,744 - $16,015	-1,646 Reduced 9.29%	16,080 $139,000
Q4 2021 Feb 14, 2022	SELL	$9.03 - $19.13 $9,030 - $19,130	-1,000 Reduced 5.34%	17,726 $168,000
Q3 2021 Nov 15, 2021	BUY	$14.31 - $18.39 $4,264 - $5,480	298 Added 1.62%	18,726 $315,000
Q2 2021 Aug 16, 2021	BUY	$15.2 - $20.94 $280,105 - $385,882	18,428 New	18,428 $281,000

Others Institutions Holding URGN

# of Institutions

130

Shares Held

35.9M

Call Options Held

22K

Put Options Held

93.8K

View Full List

About UroGen Pharma Ltd.

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $284M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

More about URGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.

Account

Royal Bank Of Canada Uro Gen Pharma Ltd. Transaction History